There's a version of this question that has a simple answer and a version that requires genuine clinical judgment. The simple answer: Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not take GLP-1 medications... and that's a hard contraindication across the class. Beyond that, though, the question of who should and shouldn't take these medications gets more nuanced, more individual, and more dependent on a complete medical picture than any checklist can capture.
GLP-1 medications require a prescription for a reason. Eligibility is determined by a licensed clinician who reviews your complete health history: not by BMI alone, not by a questionnaire, and not by what someone else in your situation was prescribed. What follows is a guide to the factors that clinicians typically evaluate, not a substitute for that evaluation.
Common Eligibility Factors Clinicians Consider
Most clinicians evaluating a patient for GLP-1 weight management therapy work through a similar set of factors, though the weight given to each varies by individual. The following are some common factors clinicians look for.
| Factor | What Clinicians Typically Look For |
|---|---|
| BMI | A BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related comorbidity |
| Weight-related comorbidities | High blood pressure, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease |
| Treatment history | Prior weight loss attempts, including lifestyle interventions, medications, and surgical options |
| Treatment goals | Degree of weight loss sought, metabolic health objectives, and realistic expectations about timeline |
| Age and product indication | Wegovy is approved for adults and adolescents aged 12 and older; Zepbound is currently approved for adults only |
| Contraindications | Contraindications: Personal or family history of MTC; MEN2; prior serious hypersensitivity to the medication or its ingredients. Important precautions: History of pancreatitis, severe gastrointestinal disease, gallbladder disease, diabetic retinopathy, and conditions that increase the risk of dehydration or kidney injury. |
| Overall benefit-risk assessment | Weighing clinical benefit against individual health history, comorbidities, concomitant medications, and patient goals |
These factors are considered together, not in isolation. A patient who meets the BMI threshold, but has a relevant contraindication may not be appropriate for treatment. A patient who falls slightly below the BMI threshold, but carries significant metabolic risk may still warrant a clinical conversation.
Medical History That May Affect Treatment
Several categories of medical history require careful evaluation before starting any GLP-1 medication. None of the following are automatic disqualifiers in every case, but all of them are factors a clinician needs to know about and weigh.
Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Wegovy and Zepbound should not be used in people with a personal or family history of medullary thyroid carcinoma (MTC), or in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). They are also contraindicated in people who have had a serious hypersensitivity reaction to semaglutide or tirzepatide, respectively, or to an ingredient in the product. Other contraindications and precautions can vary by medication, so clinicians review the labeling for the specific product being considered.
History of pancreatitis. GLP-1 medications have been associated with pancreatitis risk, including acute pancreatitis and fatal cases. A prior episode (acute or chronic) requires careful clinical evaluation before treatment is considered.
Gallbladder disease or history of gallstones. Both rapid weight loss and GLP-1 therapy have been associated with increased risk of gallbladder events. Patients with relevant history should discuss this specifically with their clinician before starting.
Gastroparesis or severe gastrointestinal motility disorders. GLP-1 medications slow gastric emptying as part of their mechanism. Patients with existing gastroparesis are generally not appropriate candidates.
Significant renal impairment. GI side effects (particularly vomiting and diarrhea) increase the risk of dehydration and acute kidney injury. Renal function should be considered as part of the intake evaluation.
History of diabetic retinopathy. Rapid improvement in blood sugar control has been associated with temporary worsening of retinopathy in some patients with type 2 diabetes. Appropriate monitoring should be discussed with a clinician.
Pregnancy or plans for pregnancy. Weight-loss treatment with Wegovy or Zepbound should be stopped when pregnancy is recognized. Semaglutide should also be stopped at least 2 months before a planned pregnancy because of its long half-life. Human pregnancy data are limited, and animal studies identified potential fetal risks.
Breastfeeding. Recommendations vary by product and formulation. Wegovy tablets are not recommended during breastfeeding. For Wegovy injection and Zepbound, patients should discuss the known and unknown risks, the benefits of breastfeeding, and their clinical need for treatment with their clinician.
History of significant eating disorders. The pronounced appetite-suppressing effects of GLP-1 medications may complicate recovery in patients with a history of restrictive eating patterns. Individual clinical assessment is especially important in this population.
Medication and Supplement Review
A complete and accurate medication list is one of the most important things a patient can bring to a GLP-1 eligibility evaluation. Several categories of medication require specific clinical attention.
Blood sugar-lowering medications. Patients taking insulin or sulfonylureas alongside a GLP-1 medication face an increased risk of hypoglycemia. In clinical trials, hypoglycemia occurred in approximately 10.3% of tirzepatide-treated patients also taking a sulfonylurea, compared to 2.1% of those not taking one. Dose adjustments to existing diabetes medications are often needed and should always be clinician-directed.
Oral hormonal contraceptives. Tirzepatide's effect on gastric emptying can reduce the efficacy of oral contraceptives. Patients taking tirzepatide should switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. This specific guidance appears in the current Zepbound prescribing label.
Oral medications with narrow therapeutic windows. GLP-1 medications slow gastric emptying and can affect the absorption timing of some oral drugs. This is particularly relevant for medications where consistent absorption matters, such as certain thyroid medications, anticoagulants, and immunosuppressants. A full medication review before starting is essential for patients on these drugs.
Other GLP-1 medications. Combining a GLP-1 medication with another product from the same class is not recommended. This includes overlapping brand-name and compounded versions of the same or different active ingredients.
Supplements. Certain supplements that affect blood sugar, appetite, or metabolic function may interact with GLP-1 therapy in ways worth discussing. Products containing berberine, high-dose chromium, or similar ingredients that influence insulin sensitivity or glucose metabolism should be disclosed during intake.
The goal of a medication review isn't to find a reason to decline treatment. It's to make sure that if treatment is prescribed, it's prescribed safely and that any necessary adjustments to existing medications are made before the patient starts.
BMI Is Not the Only Consideration
BMI is a useful population-level screening tool, but it has well-documented limitations as a measure of individual health. It doesn't distinguish between fat mass and lean mass, doesn't account for how fat is distributed in the body, and can misclassify both risk and health status across different body types and ethnic backgrounds.
In clinical practice, this matters in several specific ways. A patient with a BMI just below 30 who carries significant visceral fat, has elevated triglycerides, and a family history of type 2 diabetes may face meaningfully higher metabolic risk than the number alone suggests. Conversely, a patient with a higher BMI who is otherwise metabolically healthy may have a different risk profile than the number implies.
Current clinical guidelines for GLP-1 weight management therapy use BMI thresholds as entry criteria: a practical starting point for identifying likely candidates. But the prescribing decision accounts for the full clinical picture: comorbidity burden, treatment history, cardiovascular risk, metabolic health, and patient goals. So, BMI should certainly be the beginning of the conversation, but it's not necessarily the end of it.
What Happens During a GLP-1 Eligibility Assessment?
At Lttl, the eligibility process is designed to be thorough without being burdensome, because the quality of the clinical evaluation directly affects the safety and appropriateness of what gets prescribed.
Step 1: Complete the health intake. The process begins with a comprehensive health questionnaire covering your medical history, current medications and supplements, relevant family history, previous weight loss attempts, and your treatment goals. This takes approximately two minutes and is the foundation of the clinical evaluation that follows. The accuracy and completeness of what you disclose here directly affects what your clinician sees and how they assess your case. It is important to your health that you answer honestly, so your clinician can prescribe the most appropriate treatment (or decline one altogether if it's in the best interest of your safety).
Step 2: Licensed clinician review. A licensed clinician reviews your intake individually. This isn't an automated approval process: a real clinician reads your history, evaluates your eligibility against current clinical criteria and contraindications, and makes a prescribing decision based on your specific profile. If your intake raises questions or red flags, the clinician will follow up before making a determination.
Step 3: Lab work, if needed. Depending on your health history, the clinician may request recent lab work before finalizing a treatment plan. Metabolic panels, thyroid function, and other relevant markers help establish a clinical picture that goes beyond what a questionnaire alone can capture. If you have recent results from your primary care provider, those can often be submitted directly.
Step 4: Treatment plan or alternative guidance. If GLP-1 therapy is appropriate for you, your clinician will develop a treatment plan including medication selection, starting dose, and titration schedule. If it isn't appropriate, you'll receive a clear explanation of why and, where possible, guidance on alternatives or next steps.
What to have ready: your current medication list including supplements, any relevant recent lab results, a summary of significant medical history including surgeries and chronic conditions, and a clear sense of your weight loss goals and timeline.
Lttl currently offers compounded semaglutide at $89 per month and compounded tirzepatide at $139 per month: both all-inclusive, covering medication, clinician oversight, unlimited care team access, and shipping. Compounded semaglutide and tirzepatide are not FDA-approved and have not been independently evaluated by the FDA for safety, efficacy, or quality.
Frequently Asked Questions
I'm Overweight, but Not Obese. Can I Still Qualify?
Possibly. FDA clinical guidelines support GLP-1 therapy for adults with a BMI of 27 or higher (below the obesity threshold) if they have at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. If you fall into that category, a clinical evaluation is the right next step. If you don't meet either the BMI or comorbidity criteria, GLP-1 medications for weight management may not be clinically indicated, and a clinician will tell you that during the assessment.
Do I Need to Have Type 2 Diabetes to Qualify?
No. Wegovy and Zepbound are approved for chronic weight management in adults with obesity or overweight and a weight-related condition; diabetes is one possible qualifying comorbidity, not a requirement. Ozempic and Mounjaro, which contain the same active ingredients at different doses, are approved specifically for type 2 diabetes. These are distinct indications, and the distinction matters for how treatment is prescribed and monitored.
I've Tried Other Weight Loss Medications Before. Does That Affect Eligibility?
Prior use of weight loss medications is part of the clinical history your clinician reviews, but it doesn't automatically disqualify you. Treatment history helps inform the prescribing decision, including which medication may be a better fit and what starting dose makes sense. If you had significant GLP-1 side effects or inadequate response with a previous GLP-1 medication, that's relevant context the clinician needs to know.
Is There an Age Limit for GLP-1 Weight Management Medications?
Current FDA approvals cover adults for both Wegovy and Zepbound. Wegovy has also been approved for adolescents aged 12 and older with obesity. There is no upper age limit in the approved indications, though older adults may require additional monitoring given increased sensitivity to GI side effects and a higher baseline risk of dehydration. A clinician will factor age and overall health status into the eligibility assessment.
What if I Have a Contraindication? Are There Any Alternatives?
If a GLP-1 medication isn't appropriate based on your health history, the right next step is a conversation with a clinician about what options are available for your specific situation. Some contraindications are absolute. A history of MTC or MEN2, for example, means GLP-1 medications are not appropriate. Others may require additional evaluation or monitoring before a determination is made. A clinician can help identify the safest and most appropriate path forward based on your complete picture, which may include different medications, lifestyle interventions, or referral to a specialist.
Bibliography
- Novo Nordisk. (2026). Wegovy (semaglutide) injection and tablets: Full prescribing information (Revised March 2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
- Eli Lilly and Company. (2026). Zepbound (tirzepatide) injection, for subcutaneous use: Full prescribing information (Revised February 2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boule, N., Boyling, E., Brown, J., Calam, B., Clarke, C., Crowshoe, L., Divalentino, D., Forhan, M., Freedhoff, Y., Gagner, M.,... Wicklum, S. (2020). Obesity in adults: A clinical practice guideline. CMAJ, 192(31), E875-E891. https://www.cmaj.ca/content/192/31/E875


